GoldBamboo.com - Knowledge is strong medicine
  

Study of the Results of Education and Counseling for Persons Undergoing Genetic Testing for Hereditary Nonpolyposis Colon Cancer - Article


  Not Signed In - Sign In / Register






CF Gene Mutation


Clinical Trial: Study of the Results of Education and Counseling for Persons Undergoing Genetic Testing for Hereditary Nonpolyposis Colon Cancer

This study is currently recruiting patients.
Verified by National Cancer Institute (NCI) November 2006

Sponsors and Collaborators: National Human Genome Research Institute (NHGRI)
National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00004210

Purpose

RATIONALE: Identifying family and individual characteristics may help plan education and counseling for patients who are considering genetic testing.

PURPOSE: This clinical trial is studying education and counseling to see what effect they have in patients who are undergoing genetic testing for hereditary nonpolyposis colon cancer (recruitment of new families with HNPCC stopped as of 04-26-06, recruitment of persons within families already participating continues).

Condition Intervention
Colorectal Cancer
 Procedure: genetic analysis
 Procedure: loss of heterozygosity
 Procedure: microsatellite instability
 Procedure: mutation analysis

MedlinePlus related topics:  Colorectal Cancer
Genetics Home Reference related topics:  Colorectal Cancer

Study Type: Observational
Study Design: Natural History

Official Title: Outcomes in Education and Counseling for HNPCC Testing

Further study details as provided by National Cancer Institute (NCI):

Total Enrollment:  900

OBJECTIVES:

  • Identify family characteristics, personality traits, and religious and spiritual beliefs that significantly affect individual decisions regarding mutation testing for hereditary nonpolyposis colon cancer (HNPCC) (recruitment of new families with HNPCC stopped as of 04-26-06, recruitment of persons within families already participating continues).
  • Determine the impact of negative vs positive mutation test results on family relationships and psychological status.
  • Assess expectations regarding testing and how they influence perceptions of risks and responses to risk notification.
  • Determine the impact of risk notification on the frequency of screening/prevention activities.
  • Formulate a standard diagnostic algorithm for determining microsatellite instability based on the analysis of tumors with this extensive array of markers and correlate specific replication error phenotypes with germline genotype.

OUTLINE: Participants complete a baseline assessment of knowledge, risk perception, and personality traits followed by a structured pretest education session. Participants are then offered the choice of whether or not to undergo genetic testing for mutations in hereditary nonpolyposis colon cancer (HNPCC) genes. Participants who choose to undergo genetic testing provide a blood sample for this purpose. Participants who undergo genetic testing receive results and counseling (recruitment of new families with HNPCC stopped as of 04-26-06, recruitment of persons within families already participating continues).

Available surveillance options are discussed for all participants. Psychological and behavioral outcomes are reassessed at 6 and 12 months for both those choosing and not choosing genetic testing.

Tumors (when available) are analyzed for mismatched repair deficiency on the basis of microsatellite instability.

PROJECTED ACCRUAL: A total of 900 participants will be accrued for this study, with a specific target of 200 individuals who have not experienced cancer within families identified with hereditary nonpolyposis colon cancer (HNPCC) mutations (recruitment of new families with HNPCC stopped as of 04-26-06, recruitment of persons within families already participating continues).

Eligibility

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both
Criteria

DISEASE CHARACTERISTICS:

  • Meets one of the following criteria:

    • Family history consistent with hereditary nonpolyposis colon cancer (HNPCC)*

      • At least 3 relatives with histologically proven colorectal cancer or HNPCC-associated cancer and 1 is a first-degree relative of the other 2
      • At least 2 successive generations affected
      • Colorectal cancer (or HNPCC-associated cancer) diagnosed under age 50 in 1 of the relatives
    • Diagnosis of colorectal cancer under age 41
    • HNPCC-associated cancer/polyps* under age 41 with a microsatellite instability (MSI) phenotype
    • Multiple primary HNPCC-associated cancers* regardless of family history
    • Colorectal or other HNPCC-associated tumor/polyp* demonstrating a positive MSI phenotype and at least 1 second-degree (or closer) and 1 third-degree (or closer) relative with a HNPCC-associated cancer

      • 1 affected family member must have one of the following:

        • Right-sided colon cancer
        • Multiple primary HNPCC-associated cancers
        • Diagnosis of cancer prior to age 51 NOTE: *Recruitment of new families with HNPCC stopped as of 04-26-06, recruitment of persons within families already participating continues

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • Not specified

Life expectancy:

  • Not specified

Hematopoietic:

  • Not specified

Hepatic:

  • Not specified

Renal:

  • Not specified

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • Not specified

Endocrine:

  • Not specified

Radiotherapy:

  • Not specified

Surgery:

  • Not specified

Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier  NCT00004210


United States, Maryland
      National Human Genome Research Institute, Bethesda,  Maryland,  20892,  United States; Recruiting
Donald W. Hadley, MS  301-496-3980    dhadley@mail.nih.gov 

      National Naval Medical Center, Bethesda,  Maryland,  20889,  United States; Recruiting
Kathleen A. Calzone, RN, MSN, APNG(c)  301-435-0538    Calzonek@mail.nih.gov 

      Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda,  Maryland,  20892-1182,  United States; Recruiting
NCI Clinical Trials Referral Office  888-NCI-1937 

Study chairs or principal investigators

Donald W. Hadley, MS,  Study Chair,  National Human Genome Research Institute (NHGRI)   

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Publications that report results of this study

Hadley DW, Jenkins JF, Dimond E, de Carvalho M, Kirsch I, Palmer CG. Colon cancer screening practices after genetic counseling and testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2004 Jan 1;22(1):39-44.

Hadley DW, Jenkins J, Dimond E, Nakahara K, Grogan L, Liewehr DJ, Steinberg SM, Kirsch I. Genetic counseling and testing in families with hereditary nonpolyposis colorectal cancer. Arch Intern Med. 2003 Mar 10;163(5):573-82.

Study ID Numbers:  CDR0000067459; NCI-95-HG-0165; NCI-NMOB-9501; NHGRI-95-HG-0165
Last Updated:  February 20, 2007
Record first received:  January 21, 2000
ClinicalTrials.gov Identifier:  NCT00004210
Obsolete Identifier:   NCT00001470

Health Authority: Unspecified
ClinicalTrials.gov processed this record on May 14, 2007


Take control over your directory listings...INSTANTLY

Every day, thousands of users find businesses like yours in the GoldBamboo directory.

Limited Time Offer!!!

For only $50 a year, a savings of 50% off our standard rate:

  • Edit your listing (whenever you want!)
  • Link to your website
  • Choose which categories you are listed in
  • Describe your services

The process will take only a few minutes and consists of 3 easy steps:

1. Register     >     2. Edit Listings     >     3. Publish

Your Company
your street
yourtown, YS 12345
888-888-8888



No Thanks

Popular Treatments

Acne Treatment ADHD Treatment Allergy Treatment Alzheimer's Treatment
Anemia Treatment Arthritis Treatment Asthma Treatment Bipolar Disorder Treatment
Bird Flu Treatment Bladder Cancer Treatment Bladder Control Treatment Blood Pressure Treatment
Brain Tumor Treatment Breast Cancer Treatment Bronchitis Treatment Cancer Treatment
Cancer Alternative Treatment Cataract Treatment Cirrhosis Treatment Colitis Treatment
Colon Cancer Treatment Common Cold Treatment Conjunctivitis Treatment Constipation Treatment
Crohn's Disease Treatment Cystic Fibrosis Treatment Depression Treatment Dermatitis Treatment
Diabetes Treatment Edema Treatment Epilepsy Treatment Erectile Dysfunction Treatment
Fibromyalgia Treatment GERD Treatment Glaucoma Treatment Gout Treatment
Hay Fever Treatment Headache Treatment Heart Disease Treatment Hepatitis Treatment
High Blood Pressure Treatment High Cholesterol Treatment Hives Treatment Hypertension Treatment
Hypoglycemia Treatment IBS Treatment Impotence Treatment Indigestion Treatment
Infertility Treatment Influenza Treatment Insomnia Treatment Lactose Intolerance Treatment
Leukemia Treatment Lung Cancer Treatment Lyme Disease Treatment Macular Degeneration Treatment
Menopause Treatment Migraine Treatment Osteoarthritis Treatment Osteoporosis Treatment
Pancreatic Cancer Treatment PMS Treatment Pneumonia Treatment Prostate Diseases Treatment
Restless Leg Treatment Rheumatoid Arthritis Treatment Sepsis Treatment Sinusitis Treatment
Skin Cancer Treatment Sleep Apnea Treatment Snoring Treatment Stroke Treatment
Testicular Cancer Treatment
GoldBambooTM

Your Integrative Health and Wellness Resource for CF Gene Mutation.

September 6, 2008



Page Updated: June 1, 2005
Disclaimer: All material displayed on the GoldBamboo.com website is provided for educational purposes only. Consult a physician regarding the applicability of any information found on GoldBamboo.com to your symptoms or medical condition.

Insurance Quotes | Home | About Us | Link To Us | Feedback | Disclaimer | Privacy Policy | Terms of Use | Google Co-op | Health Forums

Copyright © 2004-2008 - Gold Bamboo LLC
All rights reserved.

HONcode accreditation seal.

We comply with the HONcode standard for health trust worthy information:
verify here.